Roche Licenses Novel Oral Rheumatoid Arthritis Agent From Japanese Firm Toyama
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal worth up to $370 million will add to Roche’s “emerging franchise” in autoimmune diseases.